传统和新型非他类降脂药物
1Department of Preventive Cardiology, Fortis-Escorts Heart Institute, Okhla Road, New Delhi, 110 025, India.
Indian heart journal
|November 18, 2023
概括
非他类药物为治疗脱脂症提供了替代方案,特别是对于他类药物不耐受患者或未达到低密度脂蛋白胆固醇 (LDL-C) 目标的患者. 新的疗法,如佩多酸和inclisiran提供额外的LDL-C降低选项.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 失脂症的管理往往需要除了他类药物之外的疗法,特别是混合失脂症,他类药物不耐受性或当LDL-C目标未达到时.
- 费诺纤维酸盐适用于严重的高甘油三血症,以预防胰腺炎,而他类药物-ezetimibe组合是常见的后急性冠状动脉综合征.
- 新兴的非他类药物为各种失脂症提供了向的降脂机制.
研究的目的:
- 审查各种非他类药物的实用性和适用性,用于治疗失脂症.
- 为了突出纤维酸,他-ezetimibe,鱼油,bempedoic 酸,inclisiran,lomitapide,mipomersen 和 pelacarsen 的特定应用.
- 讨论这些降脂剂的作用机制和关键考虑因素.
主要方法:
- 对非他类降脂疗法的文献综述.
- 药物指示,疗效和安全性概况的分析.
- 综合有关新型药物的作用机制的信息,如siRNA和抗意义寡核酸.
主要成果:
- 费诺纤维酸主要适用于高于500毫克/分升的甘油三,以减少胰腺炎的风险.
- 班佩多酸和英克利西兰有效地降低了在患有动脉样硬化心血管疾病的他类药物耐受性和不耐受性患者的LDL-C.
- 因克利西兰通过抑制PCSK-9显著降低LDL-C,而洛米塔皮德和米波梅森则向具有特定指示和风险的apoB-脂蛋白.
结论:
- 非他类药物为不同类型的失脂症和患者需求提供了关键的治疗选择.
- 新型药物如inclisiran,lomitapide和mipomersen为严重或不耐药的高脂血症提供了先进的治疗策略.
- 由于这些药物的特定指示和潜在毒性,必须对患者进行仔细的选择和监测.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
672
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
672
01:26Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
01:31Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
12
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
12
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
483
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
483
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
538
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
538